SEARCH

SEARCH BY CITATION

References

  • Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., Filiberti, A., Flechtner, H., Fleishman, S.B., De Haes, J.C., Kaasa, S., Klee, M., Osoba, D., Razavi, D., Rofe, P.B., Schraub, S., Sneeuw, K., Sullivan, M. & Takeda, F. (1993) The European Organization for Research and Treatment of Cancer QLQ C-30: a quality of life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365376.
  • Backx, B., Broeders, L. & Löwenberg, B. (1992) Kit ligand improves in vitro erythropoiesis in myelodysplastic syndromes. Blood, 80, 12131217.
  • Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R., Sultan, C. & The French–American–British (FAB) Group (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189199.
  • Casadevall, N., Durieux, P., Dubois, S., Lepage, E., Hemery, F., Quarre, M.C., Fenaux, P., Damaj, G., Giraudier, S., Guerci, A., Laurent, G., Dombret, H., Stamatoullas, A., Vekhoff, A. , Ribrag, V. & Dreyfus, F. pour le Groupe Francais des Myelodysplasies (2001) Erythropoietin (rHuEpo) plus G-CSF in the treatment of anemia in myelodysplastic syndromes (MDS): results of a randomized trial with impact on quality of life and costs. Blood, 98, 3522 (abstract).
  • Cheson, B., Bennett, J.M., Kantarijan, Pinto, A., Schiffer, C.A., Nimer, S.D., Löwenberg, B., Beral, M., De Witte, T., Stone, R., Mittelman, M., Sanz, G.F., Wijermans, P., Gore, S. & Greenberg, P. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 96, 36713674.
  • Greenberg, P.L. (1994) The myelodysplastic syndromes. In: Haematology: Basic Principles and Practice, 2nd edn (ed. by R.Hoffman, E.Benz, S.Shattil, B.Furie & H. Cohen), pp. 10981121. Churchill Livingstone, New York.
  • Greenberg, P.L., Cox, C., LeBeau, M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 20792088.
  • Hast, R., Wallvik, J., Folin, A., Bernell, P. & Stenke, L. (2001) Long-term follow-up of 18 patients with myelodysplastic syndromes with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leukemia Research, 25, 1921.
  • Hellström-Lindberg, E. (1995) Efficacy of erythropoietin in the myelodysplastic syndromes. An analysis of 205 patients in 17 studies. British Journal of Haematology, 89, 6771.
  • Hellström-Lindberg, E., Kanter-Lewensohn, L. & Öst, Å. (1997a) Morphological changes and apoptosis in bone marrow from patients treated with granulocyte-CSF and erythropoietin. Leukemia Research, 21, 415455.
  • Hellström-Lindberg, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., Vardiman, J., Öst, Å. & Greenberg, P. (1997b) Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndromes: proposal for a predictive model. British Journal of Haematology, 99, 344351.
  • Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I.M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Nilsson-Ehle, H., Samuelsson, J., Tangen, J.M., Winqvist, I., Oberg, G., Osterborg, A. & Öst, Å. (1998) Treatment of the anemia in myelodysplastic syndromes with granulocyte-CSF plus erythropoietin: results from a randomized phase II study and long-term follow-up on 71 patients. Blood, 92, 6875.
  • Hellström-Lindberg, E., Willman, C., Barrett, A.J. & Saunthararajah, Y. (2000) Achievements in Understanding and Treatment of Myelodysplastic Syndromes. Haematology 2000, pp. 110132. American Society of Haematology, Washington, DC.
  • Hilden, J., Habbema, J.D.F. & Bjerregaard, B. (1978) The measurement of performance in probabilistic diagnosis. II. Trustworthiness of the exact values of the diagnostic probabilities. Methods in Infectious Medicine, 17, 227237.
  • Hjermstad, M.J., Fossa, S.D., Bjordal, K. & Kaasa, S. (1995) Test/retest study of the European Organization for Research and Treatment of Cancer core quality of life questionnaire. Journal of Clinical Oncology, 13, 12491254 .
  • Hjermstad, M.J., Fayers, P.M., Bjordal, K. & Kaasa, S. (1998a) Health Related Quality of Life in the general population assessed by the EORTC Core Quality of Life Questionnaire – the EORTC QLQ-C30 (+3) Journal of Clinical Oncology, 16, 11881196.
  • Hjermstad, M.J., Fayers, P.M., Bjordal, K. & Kaasa, S. (1998b) Using reference data on quality of life – the importance of adjusting for age and sex, exemplified by the EORTC QLQ-C30 (+3). European Journal of Cancer, 34, 13811389.
  • Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodyplastic syndromes. British Journal of Haematology, 103, 10701074.
  • Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (eds) (2001). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. IARC Press, Lyon.
  • Kaasa, S., Bjordal, K., Aaronson, N., Moum, T., Wist, E., Hagen, S. & Kvikstad, A. (1995) The EORTC Core Quality of Life Questionnaire (QLQ C-30): validity and reliability when analyzed with patients treated with palliative radiotherapy. European Journal of Cancer, 31A, 22602263.
  • Kornblith, A.B., Herndon, I.I.J.E., Silverman, L.R., Demakos, E.P., Odchimar-Reissig, R., Holland, J.F., Powell, B.L., DeCastro, C., Ellerton, J., Larson, R.A., Schiffer, C. & Holland, J.C. (2002) Impact of azacytidine on the quality of life of patients with the myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia group B study. Journal of Clinical Oncology, 20, 24412452.
  • Mantovani, L., Lentini, G., Hentschel, B., Wickramanayake, P.D., Loeffler, M., Diehl, V. & Tesch, H. (2000) Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor. British Journal of Haematology, 109, 367375.
  • Negrin, R.S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J., Krantz, S. & Greenberg, P.L. (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood, 87, 40764081.
  • Osoba, D., Rodrigues, G., Myles, J., Zee, B. & Pater, J. (1998) Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16, 139144.
  • Raza, A., Gezer, S., Mundle, S., Gao, X.Z., Alvi, S., Borok, R., Rifkin, S., Iftikhar, A., Shetty, V., Parcharidou, A., Loew, J.M., Marcus, B., Khan, Z., Chaney, C., Showel, J., Gregory, S. & Preisler, H. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood, 86, 268276.
  • Remacha, A.F., Arrizabalaga, B., Villegas, A., Manteiga, R., Calvo, T., Julia, A., Fernandez Fuertes, I., Gonzalez, F.A., Font, L., Junca, J., Del Arco, A., Malcorra, J.J., Equiza, E.P., De Mendiguren, B.P. & Romero, M. (1999) Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica, 84, 10581064,.
  • Schmidt-Mende, J., Tehranchi, R., Forsblom, A.M., Joseph, B., Christensson, B., Fadeel, B., Zhivotovsky, B., Hellström-Lindberg, E. & Hellström-Lindberg, E. (2001) Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia, 15, 742751.
  • Spiegelhalter, D.J. (1983) Evaluation of clinical decision-aids, with application to a system for dyspepsia. Statistics in Medicine, 2, 207216.
  • Tehranchi, R., Fadeel, B., Forsblom, A.M., Christensson, B., Samuelsson, J., Zhivotovsky, B. & Hellstrom-Lindberg, E. (2003) Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood, 101, 10801086.
  • Thomas, M. (2001) Quality of life in myelodysplastic syndromes: Measurement issues in research and in clinical practice. Leukemia Research, Suppl. 1, Or28 (abstract).
  • Van de Loosdrecht, A.A. & Vellenga, E. (2000) Myelodysplasia and apoptosis: new insights into ineffective erythropoiesis. Medical Oncology, 17, 573578.
  • Wisloff, F., Hjorth, M., Kaasa, S. & Westin, J. (1996) Measurement of health-related quality of life in multiple myeloma. British Journal of Haematology, 92, 604613.